Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2018

View Archived Issues

Neuraly enrolling participants in phase I study of NLY-01

Interferon, protease contribute to post-viral bacterial infections

HGPS and the heart

NK problems facilitate bnAbs in HIV

Toil and tribbles

Genome editing fixes mitochondrial DNA

Medshine Discovery and collaborators patent TP53-MDM2 interaction inhibitors

Bristol-Myers Squibb initiates phase III study of NKTR-214 plus nivolumab in metastatic melanoma

Patient recruitment is ongoing in phase II study of BI-730357 in plaque psoriasis

Phase I study of Butantan Institute's H7N9 influenza antigen

Mylan initiates phase III comparative study of MYL-1701P and Eylea

Salk awarded CIRM grant to support development of immune-tolerant human islet-like organoids

Ocugen initiates the first trial in its phase III program of OCU-310 in dry eye disease

Yervoy, Opdivo go to Stockholm: 2018 Medicine Nobel honors checkpoint inhibitor work

Kigabeq granted European marketing authorization

Patient recruitment ongoing in phase II study of PRCL-02 in chronic plaque psoriasis

CHIT1 unveiled as a novel therapeutic target in IPF

FDA approves once-weekly dosing option for Kyprolis in relapsed or refractory multiple myeloma

Omeros reports further phase II data on OMS-721 in IgA nephropathy

Dragonfly Therapeutics and Merck & Co. establish cancer immunotherapy collaboration

FDA approves Xyosted auto-injector for testosterone replacement

Novel humanized mouse model for idiopathic pulmonary fibrosis

A new model of persistent retinal neovascularization better reflects the human disease phenotype

Shenzhen Targetrx Biotechnology synthesizes new VEGFR inhibitors

Bromodomain-containing protein 4 inhibitors discovered at GlaxoSmithKline

Guangzhou Maxinovel Pharmaceuticals patents adenosine A2A receptor antagonists

Shanghai Institute of Materia Medica presents BRD4 inhibitors

Foamix reports further data from third phase III trial of FMX-101 for moderate to severe acne